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suggests that stigmatization around schizophrenia and major depression is pres-
ent in France; the public willing to help mental disease patients as demonstrated by
our study, stress on the relevance of investing in mental health to reduce the
enormous associated costs that burden individuals, families and societies. This
stigmatization contributes to marginalize patients, exclude them from health care
management and affects their disease severity. Impact of stigma on willingness to
pay is being assessed.
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OBJECTIVES: Health care systems face increased prevalence and costs of mental
illness. The objective of this study is to provide a comprehensive overview of per-
sonalized medicine for major psychiatric disorders with focus on developing mo-
lecular imaging biomarker.METHODS:A systematic review was conducted to iden-
tify current molecular imaging methods in psychiatric disorders. The following
databases were searched between 2009 to February 2012: Medline, PubMed, Sco-
pus, Cochrane Library, PsycINFO, Psychiatry Online Journals, PSYINDEX as well as
individual journals. The extraction of data consisted of the biomarker, tracer and
the targeted disease. According to Fryback and Thornbury, the level of diagnostic
efficiency was defined as selection criterion for the technology. The most promis-
ing biomarker was then examined by indication, treatment phase and stage of
development. An update search for the identified technology was the performed
following the PRISMA guidelines. RESULTS: Several emerging molecular imaging
technologies were identified, but most imaging technologies still have to prove
technical efficiency. The most mentioned radiotracers are Pittsburgh Compound B
for amyloid imaging (45 articles) in Alzheimer’s disease, Raclopride for dopamine 2
imaging (25 articles) and DASB for Serotonin 1A imaging (17 articles). Within this,
amyloid imaging is the most advanced technology. Thirty-one studies examined
patients with and without diagnosis of Alzheimer’s disease. Amyloid imaging pro-
vides a high reliability in diagnosis, but cognitive measures only showed weak
correlations. CONCLUSIONS: The current status of molecular imaging in psychia-
try was assessed. The most promising technology, amyloid imaging in Alzheimer’s
disease, is expected to improve the diagnosis, therapy, as well as the organisation
of care. Preclinical diagnosis can be a base for further treatment options like anti-
amyloid therapy. “Personalized medicine” like molecular imaging offers an effec-
tive solution for an accurate screening, diagnosis and treatment.
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OBJECTIVES: Bipolar disorder (BD) is a psychiatric disease characterized by recur-
ring mood episodes. One pharmacological treatment for BD is quetiapine fumarate,
which exists in two formulations; extended release (XR) and immediate release
(IR). The aim was to describe patient characteristics and treatment patterns for BD
patients treated with quetiapine IR continuously vs. patients who were switched to
XR. METHODS: BD patients with hospital admittance and prescription of quetiap-
ine were identified from the Swedish National Patient Register and linked to the
Prescribed Drug Register (ctw.gov, NCT01455961). Index date was defined as first
prescription of quetiapine XR or first prescription of IR after 1st January 2009. End of
observation was 31st December 2011. Data were analyzed by descriptive methods.
RESULTS:A total of 5219 BD patients with prescriptions of XR/IR were identified. Of
the 1761 patients using IR; 1303 patients later switched to XR, whereas 458 patients
continuously used IR during the study period. Patients who later switched from IR
to XR had more single depressions (47.1 vs. 40.4%) and anxiety disorders (36.1 vs.
30.3%), lower mean quetiapine IR dose (218 vs. 270 mg), and less medications for
somatic diseases (39.0 vs. 46.5%), compared to patients continuing on IR. Following
switch to XR, the number of concomitant medications (atypical antipsychotics and
antidepressants) was reduced by 5.9 and 6.0%; while it increased by 3.0 and 0.7% in
the IR continuous group, respectively. The quetiapine dose post-switch was higher
in the group that switched to XR vs. the IR continuous group, 305 vs. 252 mg.
CONCLUSIONS: Patients with bipolar disorder who switched to quetiapine XR had
more psychiatric co-morbidity before switch compared to continuous IR patients.
Following switch to XR, a higher mean quetiapine dose compared to the continu-
ous IR group, and a decreased use of concomitant medications was found in this
patient group.
PMH51
REAL WORLD ADD-ON AND SWITCH PATTERNS FOR DIFFERENT
FORMULATION OF METHYLPHENIDATE
Håkan-Mose J, Löfroth E, Huetson P
IMS Health, Stockholm, Sweden
OBJECTIVES: To analyze the add-on and switch patterns for patients who dis-
pensed different formulation of methylphenidate, in the South-West region of
Sweden. METHODS: This was a retrospective database study of medication utili-
zation amongst patients from the South-West region of Sweden (1.5 million inhab-
itants). All patients who dispensed Methylphenidate (ATC code: N06BA04), from
2006 to 2010 were included in the study. A dispatch was classified as new, switch,
add-on, or continuation. All dispatches were annotated, at the drug type level, as
either new (no other methylphenidate products within 90 days), add-on (another
methylphenidate products dispatched both before and after), switch (another
methylphenidate products dispatched before, but not after), or continuation (dis-
patched same drug type within 90 days). RESULTS: A total of 11731 patients had at
least one methylphenidate filled prescription. The total number of dispatches for
these patients were 219 750. 77% of all patients had been dispatched long acting
methylphenidate, 44% modified release methylphenidate and 30% short acting
methylphenidate. Long acting methylphenidate was dispatched as a new prescrip-
tion in 19% of all dispatches, in 0.5% as add-on, 0.9% as switch, and in 80% as
continuation. For modified release methylphenidate the distribution was 15%
(new), 1% (add-on), 3% (switch), and 81% (continuation). For short acting methyl-
phenidate the distribution was 10%, 10%, 8%, and 72%. CONCLUSIONS: Long acting
methylphenidate is the most dispatched product type. Both long acting and mod-
ified release methylphenidate had first line treatment profiles, of which it was most
pronounced for long acting methylphenidate (1% add-on or switch). Short acting
methylphenidate is used more as an add-on or switch therapy with 10% as add-on,
8% as switch, and only 10% as new dispatches.
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OBJECTIVES: The primary objective was to compare medical resource use and cost
amongst patients diagnosed with anorexia nervosa (AN), bulimia nervosa (BN), and
binge eating disorder (BED). METHODS: Eating disorders were identified retrospec-
tively using IMS LifeLink claims data from January 2006 through June 2010. Eating
disorder not otherwise specified (EDNOS) patients were subdivided into two
groups: obese and non-obese. BED does not currently have a DSM-IV diagnosis, so
obese subjects coded with EDNOS were used as a proxy for BED patients. Comor-
bidities, treatments, health care utilization, and costs were collected for 12 months
before and after an eating disorder diagnosis. To compare outcomes in the fol-
low-up period, Propensity Score Matching (PSM) was used to match each eating
disorder cohort to a comparable control group based on pre-index demographic
and clinical characteristics. RESULTS: Obese EDNOS patients had higher health
care resource utilization than all other eating disorder groups. The biggest differ-
ence came from non-psychiatric related inpatient visits. Obese EDNOS patients
(N4,534) had a total cost of $19,063 compared to $9,362 for the reference group
(p-value0.001); non-obese EDNOS patients (N4,401) total cost was $10,022 vs.
$5,444 for the controls (p-value0.001). AN patients (N1,942) had an average total
cost of $14,961 versus $6,828 for the control patients (p-value0.001) while BN
patients (N2,334) had an average total cost of $9,980 versus $5,840 for the controls
(p-value0.001).CONCLUSIONS:Compared to matched control groups, health care
costs were significantly greater for each eating disorder group. More frequent in-
patient, outpatient, and outpatient ER visits characterized all three treatment
groups. Overall, BED patients appear to have had the highest average annual cost of
all cohorts.
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OBJECTIVES: With population aging across European countries, Alzheimer’s dis-
ease (AD) represents an increasing burden for societies and health care payers. The
present study assessed the health-economic potential benefits of hypothetical in-
terventions in preventing AD across 9 European countries. METHODS: A 3-state
dynamic Markov model was developed in a population of 65 year old patients.
Age-specific conversion rates from No AD to AD were retrieved from a European
study. On top of the non-specific mortality rates, an adjustment factor was applied
to patients with AD. Annual costs data for AD were retrieved for 9 major European
countries including France, Germany and the UK. These costs (societal perspective)
ranged from €9,856 in Ireland to €36,885 in the UK. Two preventing AD interven-
tions were simulated, based on relative risk reductions (RRR) of 0.8 and 0.5.
RESULTS: In order to be break-even, annual costs of interventions ranged from €90
in Denmark, Ireland and Sweden to €335 in the UK and from €230 up to €831 in the
same countries, respectively for interventions with RRR 0.8 and 0.5. For a given
willingness to pay of €50,000, interventions were cost-effective in France at €380
and €970, in Germany at €290 and €770, respectively for RRR of 0.8 and 0.5. For these
2 interventions, average per patients expected savings ranged from €1,859 and
€4,829, respectively for RRR 0.8 and 0.5, in Belgium. The demographic projections
led in France to a reduction of AD prevalent patients of 25,295 (0.8) and 66,334 (0.5)
cases. This translated into annual savings in France of €559 million and €1.465
billion, respectively for RRR of 0.8 and 0.5. CONCLUSIONS: These analyses demon-
strate the large potential health-economic benefits of AD preventing interventions.
The results are robust across 9 major European countries and should encourage
intervention development and financing.
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